 | Up a level |
Kasmann, Lukas, Niyazi, Maximilian, Blanck, Oliver 
ORCID: 0000-0003-1391-1308, Baues, Christian, Baumann, Rene, Dobiasch, Sophie, Eze, Chukwuka, Fleischmann, Daniel, Gauer, Tobias, Giordano, Frank A., Goy, Yvonne, Hausmann, Jan, Henkenberens, Christoph, Kaul, David, Klook, Lisa, Krug, David ORCID: 0000-0001-8811-5416, Maeurer, Matthias, Panje, Cedric M., Rosenbrock, Johannes, Sautter, Lisa, Schmitt, Daniela ORCID: 0000-0002-9657-0715, Suess, Christoph, Thieme, Alexander H., Trommer-Nestler, Maike, Ziegler, Sonia ORCID: 0000-0001-8655-3172, Ebert, Nadja, Medenwald, Daniel and Ostheimer, Christian
(2018).
Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer A systematic review.
Strahlenther. Onkol., 194 (2).
S. 79 - 91.
HEIDELBERG:
SPRINGER HEIDELBERG.
ISSN 1439-099X
Seier, Johanna A., Reinhardt, Julia, Saraf, Kritika, Ng, Susanna S., Layer, Julian P., Corvino, Dillon, Althoff, Kristina, Giordano, Frank A., Schramm, Alexander, Fischer, Matthias and Hoelzel, Michael (2021). Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma. J. Immunother. Cancer, 9 (5). LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426
Zeyen, Thomas, Potthoff, Anna-Laura, Nemeth, Robert, Heiland, Dieter H., Burger, Michael C., Steinbach, Joachim P., Hau, Peter, Tabatabai, Ghazaleh, Glas, Martin, Schlegel, Uwe, Grauer, Oliver, Krex, Dietmar, Schnell, Oliver, Goldbrunner, Roland, Sabel, Michael ORCID: 0009-0000-1485-7820, Thon, Niklas, Delev, Daniel, Clusmann, Hans, Seidel, Clemens, Gueresir, Erdem, Schmid, Matthias ORCID: 0000-0002-0788-0317, Schuss, Patrick ORCID: 0000-0002-5806-2576, Giordano, Frank A., Radbruch, Alexander, Becker, Albert, Weller, Johannes, Schaub, Christina, Vatter, Hartmut, Schilling, Judith, Winkler, Frank ORCID: 0000-0003-4892-6104, Herrlinger, Ulrich and Schneider, Matthias
(2022).
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Trials, 23 (1).
LONDON:
BMC.
ISSN 1745-6215